<DOC>
	<DOC>NCT01056731</DOC>
	<brief_summary>This is an open-label, not controlled, sequential, dose escalation study of 16 weeks' duration. The study is composed of two periods: a 0-2 week optional wash-out period depending on previous antihypertensive treatment(s), followed by a 16-week open-label active treatment period. Patients will be evaluated every 4 weeks during period 2. Treatment will start with Aliskiren 150 mg with dose titration to Aliskiren 300 mg, and addition of HCTZ 12,5 mg and 25 if control of BP is not achieved (&lt; 140/90 mmHg or 130/ 80 mmHg in diabetics patients). All patients who have reached their BP target will be considered as having met the primary endpoint and this visit will be considered as the final visit.</brief_summary>
	<brief_title>A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Outpatients, with essential hypertension, stage III, naïve or not controlled with monotherapy. BP&gt; 180/110 mmHg Pregnant or nursing women Hypertensive encephalopathy or cerebrovascular accident, transient ischemic cerebral attack, myocardial infarction, unstable angina, coronary bypass surgery, percutaneous coronary intervention within 6 month K &lt;3.5 mEq/L or ≥ 5 mEq/L Renal impairment Hypersensitivity to HCTZ or Aliskiren or angioedema due to ACEI or ARB Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>high blood pressure</keyword>
	<keyword>aliskiren</keyword>
	<keyword>hydrochlorothiazide</keyword>
	<keyword>control rate</keyword>
</DOC>